Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Valve repair may unlock higher doses of heart meds

NCT ID NCT07578129

Not yet recruiting Knowledge-focused Sponsor: Ceric Sàrl Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This observational study will enroll 50 adults with severe tricuspid regurgitation (a leaky heart valve) and reduced heart function. Researchers want to see if repairing the valve with the PASCAL Precision System allows patients to safely increase their heart failure medications over 12 months. Participants will be followed to track medication doses, hospitalizations, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEFT VENTRICULAR DYSFUNCTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.